ReviewCureus2023
Anemia and Hypoxia Impact on Chronic Kidney Disease Onset and Progression: Review and Updates.
Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Prognostic impact of sleep-disordered breathing on mortality and cardiovascular events in renal dialysis: A meta-analysis.Biomolecules & biomedicine · 2025Pooled it
- Effectiveness and safety of Shengxuening for treatment of renal anemia: a comprehensive systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Trial
- Association Between Preoperative Anemia and Incident Chronic Kidney Disease after Metabolic and Bariatric Surgery: a Propensity Score-matched Cohort Study.Obesity surgery · 2026Article
- Non-linear relationship between BMI and eGFR at admission in elderly patients with hip fractures: a retrospective cross-sectional study.BMC geriatrics · 2026Article
- Article
- The Lung-Kidney Axis: A Coordinated Regulation of Oxygen Sensing and Erythropoiesis.Biomedicines · 2026Review
- Dynamic Hemoglobin Trajectories in Renal Anemia and Their Association with Frailty Progression and Cardiovascular Events in Non-Dialysis Chronic Kidney Disease.Mediterranean journal of hematology and infectious diseases · 2026Article
- From albuminuria to multi-omics signatures: emerging biomarkers and drug targets for early-stage chronic kidney disease.Frontiers in pharmacology · 2026Review
- Review
- Predictors of rapid eGFR decline in early to moderate chronic kidney disease (stages G1-G4): insights from a real-world Thai cohort incorporating KDIGO 2024 guidelines.Renal failure · 2025Article
- Article
- Machine learning for risk prediction of acute kidney injury in patients with diabetes mellitus combined with heart failure during hospitalization.Scientific reports · 2025Article
- Review
- Reducing mortality in acute kidney disease through comprehensive laboratory support: Findings from the ICLATA hybrid implementation study in Zambia.PLOS global public health · 2025Article
- Progressive Deactivation of Hydroxylases Controls Hypoxia-Inducible Factor-1α-Coordinated Cellular Adaptation to Graded Hypoxia.Research (Washington, D.C.) · 2025Article
- Renal Findings in Patients with Thalassemia at Abdominal Ultrasound: Should We Still Talk about "Incidentalomas"? Results of a Long-Term Follow-Up.Diagnostics (Basel, Switzerland) · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is caused by hypoxia in the renal tissue, leading to inflammation and increased migration of pathogenic cells. Studies showed that leukocytes directly sense hypoxia and respond by initiating gene transcription, encoding the 2-integrin adhesion molecules. Moreover, other mechanisms participate in hypoxia, including anemia. CKD-associated anemia is common, which induces and worsens hypoxia, contributing to CKD progression. Anemia correction can slow CKD progression, but it should be cautiously approached. In this comprehensive review, the underlying pathophysiology mechanisms and the impact of renal tissue hypoxia and anemia in CKD onset and progression will be reviewed and discussed in detail. Searching for the latest updates in PubMed Central, Medline, PubMed database, Google Scholar, and Google search engines were conducted for original studies, including cross-sectional studies, cohort studies, clinical trials, and review articles using different keywords, phrases, and texts such as "CKD progression, anemia in CKD, CKD, anemia effect on CKD progression, anemia effect on CKD progression, and hypoxia and CKD progression". Kidney tissue hypoxia and anemia have an impact on CKD onset and progression. Hypoxia causes nephron cell death, enhancing fibrosis by increasing interstitium protein deposition, inflammatory cell activation, and apoptosis. Severe anemia correction improves life quality and may delay CKD progression. Detection and avoidance of the risk factors of hypoxia prevent recurrent acute kidney injury (AKI) and reduce the CKD rate. A better understanding of kidney hypoxia would prevent AKI and CKD and lead to new therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.